gms | German Medical Science

Deutscher Rheumatologiekongress 2023

51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)
37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)
33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

30.08. - 02.09.2023, Leipzig

Article

Send article

Blood-based biomarkers of tissue remodeling and inflammation can discriminate between rheumatic diseases and healthy controls, and are associated with hand function

Meeting Abstract

Search Medline for

  • Helena Port - Uni Kopenhagen, København; Nordic Bioscience A/S, Herlev, Copenhagen
  • Birte Coppers - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Sara Bayat - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Elie Tino Godonou - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Larissa Valor-Méndez - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • David Simon - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Filippo Fagni - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Giulia Corte - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Koray Tascilar - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Axel Hueber - Paracelsus Medizinische Privatuniversität Nürnberg, Division of Rheumatology, Nürnberg
  • Verena Schönau - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Michael Sticherling - Universitätsklinikum Erlangen, Dermatology, Erlangen
  • Sigrid Leyendecker - Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Applied Dynamics, Erlangen
  • Daniela Bohr - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Georg Schett - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Arnd Kleyer - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen
  • Signe Holm Nielsen - Nordic Bioscience A/S, Herlev, Copenhagen
  • Anna-Maria Liphardt - Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunolog, Erlangen; Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Leipzig, 30.08.-02.09.2023. Düsseldorf: German Medical Science GMS Publishing House; 2023. DocET.04

doi: 10.3205/23dgrh024, urn:nbn:de:0183-23dgrh0245

Published: August 30, 2023

© 2023 Port et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Introduction: Physical impairment and inflammatory degenerative processes are hallmarks of auto-inflammatory diseases such as rheumatoid arthritis (RA), psoriasis (PsO) and psoriatic arthritis (PsA) [1]. During inflammation, an accelerated extracellular matrix (ECM) tissue remodeling occurs, leading to unique protease-mediated degradation products of proinflammatory molecules and collagens being released into circulation and quantifiable in serum. We investigated whether ECM biomarker levels were different among rheumatic diseases compared to healthy controls, and whether they were associated with measurements of hand function.

Methods: This is a secondary analysis of serum samples from participants of two hand function studies [1] with identical study procedures for sample collection and assessments. Serum samples were obtained from patients with RA (n=85), PsO (n=96) and PsA (n=107) patients, and from healthy controls (n=50) in the outpatient clinic of the Internal Medicine 3 (Rheumatology and Immunology), Universitätsklinikum Erlangen. Biomarkers of aggrecan (ARG), type I, III and IV collagen (C1M, C3M and C4M) degradation, and a biomarker of macrophage activity (citrullinated and MMP-degraded vimentin; VICM) were measured using immunoassays from Nordic Bioscience A/S. The Moberg-Picking-Up Test (MPUT) [2] and the Michigan Hand Questionnaire (MHQ) [3] were used to evaluate hand function. Differences between biomarker levels among the groups were compared by Kruskal Wallis tests and associations between the biomarkers and hand function parameters in patients with RA, PsO and PsA by Spearman correlations.

Results: ARG and VICM presented higher levels in patients with RA, PsO and PsA compared to healthy controls (Figure 1 A [Fig. 1] and E [Fig. 1], p<0.05). C1M, C3M and C4M were elevated in patients with PsO and PsA compared to RA (Figure 1 B [Fig. 1], C[Fig. 1] and D [Fig. 1], p<0.05). C1M also presented higher levels in patients with PsO compared to PsA, and together with C3M they showed greater levels than in healthy controls (Figure 1 B [Fig. 1] and C [Fig. 1], p<0.05). Among these biomarkers, C1M and VICM were significantly associated with MPUT (ρ=-0.2, ρ=0.1, respectively, both p<0.01), and only C1M with the MHQ (ρ=0.2, p<0.01).

Conclusion: ECM remodeling biomarkers were altered in patients with rheumatic diseases compared to healthy controls, reflecting inflammation-driven tissue damage, and were associated with hand function impairment.

Outline

References

1.
Liphardt AM, Manger E, Liehr S, Bieniek L, Kleyer A, Simon D, Tascilar K, Sticherling M, Rech J, Schett G, Hueber AJ. Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function. ACR Open Rheumatol. 2020 Dec;2(12):734-40. DOI: 10.1002/acr2.11196 External link
2.
Ng CL, Ho DD, Chow SP. The Moberg pickup test: results of testing with a standard protocol. J Hand Ther. 1999 Oct-Dec;12(4):309-12. DOI: 10.1016/s0894-1130(99)80069-6 External link
3.
Waljee JF, Chung KC, Kim HM, Burns PB, Burke FD, Wilgis EF, Fox DA. Validity and responsiveness of the Michigan Hand Questionnaire in patients with rheumatoid arthritis: a multicenter, international study. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1569-77. DOI: 10.1002/acr.20274 External link